68 related articles for article (PubMed ID: 29341428)
21. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
22. LncRNA
Cruickshank BM; Wasson MD; Brown JM; Fernando W; Venkatesh J; Walker OL; Morales-Quintanilla F; Dahn ML; Vidovic D; Dean CA; VanIderstine C; Dellaire G; Marcato P
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072264
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cell characteristics and their potential as therapeutic targets.
Lim JR; Mouawad J; Gorton OK; Bubb WA; Kwan AH
Med Oncol; 2021 May; 38(7):76. PubMed ID: 34050825
[TBL] [Abstract][Full Text] [Related]
24. Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance.
Xiao H; Zheng Y; Ma L; Tian L; Sun Q
Front Pharmacol; 2021; 12():648407. PubMed ID: 33953682
[TBL] [Abstract][Full Text] [Related]
25. Immune evasion by cancer stem cells.
Tsuchiya H; Shiota G
Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
[TBL] [Abstract][Full Text] [Related]
26. Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA).
Xing Q; Liu S; Jiang S; Li T; Wang Z; Wang Y
Transl Androl Urol; 2020 Oct; 9(5):2054-2070. PubMed ID: 33209669
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of cancer stem cell formation and maintenance.
French R; Pauklin S
Int J Cancer; 2021 Jun; 148(12):2884-2897. PubMed ID: 33197277
[TBL] [Abstract][Full Text] [Related]
28. Cellular plasticity in bone metastasis.
Fang C; Kang Y
Bone; 2022 May; 158():115693. PubMed ID: 33069922
[TBL] [Abstract][Full Text] [Related]
29. Cellular Plasticity in Breast Cancer Progression and Therapy.
Kong D; Hughes CJ; Ford HL
Front Mol Biosci; 2020; 7():72. PubMed ID: 32391382
[TBL] [Abstract][Full Text] [Related]
30. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
[TBL] [Abstract][Full Text] [Related]
31. The age of immunotherapy-Celebrating STEM CELLS' contribution to understanding mechanisms of immune system development and modulation.
Nolta JA
Stem Cells; 2020 Jan; 38(1):4-5. PubMed ID: 31851396
[No Abstract] [Full Text] [Related]
32. The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.
Ravindran S; Rasool S; Maccalli C
Cancer Microenviron; 2019 Dec; 12(2-3):133-148. PubMed ID: 31758404
[TBL] [Abstract][Full Text] [Related]
33. The Flick of a Switch: Conferring Survival Advantage to Breast Cancer Stem Cells Through Metabolic Plasticity.
Walsh HR; Cruickshank BM; Brown JM; Marcato P
Front Oncol; 2019; 9():753. PubMed ID: 31552162
[TBL] [Abstract][Full Text] [Related]
34. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.
Vidovic D; Huynh TT; Konda P; Dean C; Cruickshank BM; Sultan M; Coyle KM; Gujar S; Marcato P
Cell Death Differ; 2020 Jan; 27(1):363-378. PubMed ID: 31197235
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-92 Expression in CD133
Shidal C; Singh NP; Nagarkatti P; Nagarkatti M
Cancer Res; 2019 Jul; 79(14):3622-3635. PubMed ID: 31015227
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications.
Darvin P; Sasidharan Nair V; Elkord E
J Oncol; 2019; 2019():3958908. PubMed ID: 30915120
[TBL] [Abstract][Full Text] [Related]
37. The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways.
Xu M; Almasi S; Yang Y; Yan C; Sterea AM; Rizvi Syeda AK; Shen B; Richard Derek C; Huang P; Gujar S; Wang J; Zong WX; Trebak M; El Hiani Y; Dong XP
Cell Calcium; 2019 May; 79():80-88. PubMed ID: 30889511
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic Silencing of TAP1 in Aldefluor
Sultan M; Vidovic D; Paine AS; Huynh TT; Coyle KM; Thomas ML; Cruickshank BM; Dean CA; Clements DR; Kim Y; Lee K; Gujar SA; Weaver ICG; Marcato P
Stem Cells; 2018 May; 36(5):641-654. PubMed ID: 29341428
[TBL] [Abstract][Full Text] [Related]
39. The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its inhibition by viral immune evasion proteins.
Praest P; Luteijn RD; Brak-Boer IGJ; Lanfermeijer J; Hoelen H; Ijgosse L; Costa AI; Gorham RD; Lebbink RJ; Wiertz EJHJ
Mol Immunol; 2018 Sep; 101():55-64. PubMed ID: 29879547
[TBL] [Abstract][Full Text] [Related]
40. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
